Clinical trials: Metabolic Disorder
Hyperlipidemia
A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet
People who follow a low-carbohydrate diet typically experience a decrease in triglycerides and increase in HDL-C level, but fail to lower their LDL cholesterol (LDL-C). Such patients may require lipid-lowering therapy.
- Trial name
- LOCUST (NCT00566267)
- Testing
- simvastatin 20 mg/ezetimibe
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects
This study is conducted in Asia. The aim of this observational study is to investigate the percentage of patients reaching the treatment target on blood glucose control after treatment with either human insulin or insulin…
- Trial name
- NCT00806936
- Testing
- human insulin, insulin analogue
- Where
- China
- Volunteers
- 4,847 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
Primary Objectives: To assess efficacy in terms of change from baseline in Hemoglobin A1c (HbA1c) at the end of study between the two drugs.
- Trial name
- ACADEMIC (NCT03794336)
- Testing
- Alogliptin, Acarbose, Metformin
- Where
- China
- Volunteers
- 1,293 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Safety of ENC-201-CED ENCRT
The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a subcutaneous space in patients with Type I diabetes.
- Trial name
- NCT06408311
- Testing
- ENC-201-CED hPI
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Encellin
Type 2 Diabetes Mellitus
Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin
Primary Objective: To evaluate the efficacy of fixed dose combination of glimepiride and metformin (AMARYL M 1/250mg) in comparison with glimepiride (AMARYL) alone in terms of glycemic control as reflected by HbA1c during a…
- Trial name
- NCT01457911
- Testing
- Glimepiride and Metformin hydrochloride combination (HOE490), Glimepiride (HOE490)
- Where
- 22 sites in China
- Volunteers
- 244 people
- Sponsor
- Sanofi
Hypertension, Ischemic Heart Disease
Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment
This clinical investigation will evaluate a novel contactless technology for assessing arterial stiffness and explore its potential in assessment of risk for and development of cardiovascular disease.
- Conditions
- Hypertension, Ischemic Heart Disease, Valvular Heart Disease, Heart Failure
- Trial name
- NCT06984211
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT00138671
- Testing
- Subcutaneous Insulin, Inhaled Insulin
- Where
- 88 sites in United States, Brazil and 3 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
Osteoporosis
HDDO-1614 Intervention Trial
Randomized, Open-label, Single-dose, 3-period, 6-sequence, 3-way crossover Study
- Trial name
- NCT03234244
- Testing
- Bazedoxifene 20 mg, Cholecalciferol, Bazedoxifene 20mg and Cholecalciferol
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Hyundai Pharmaceutical Co., LTD.
Healthy Volunteers, Hepatic Insufficiency
A Single Dose Study of LY2605541 in Participants With Liver Impairment
The primary purpose of this study is to help answer the following research questions: To evaluate how much of the study drug (LY2605541) is in the blood of participants with varying degrees of liver impairment compared to those…
- Conditions
- Healthy Volunteers, Hepatic Insufficiency, Diabetes Mellitus, Type 2
- Trial name
- NCT01751399
- Testing
- LY2605541
- Where
- 2 sites in Germany, Hungary
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1…
- Trial name
- NCT03993132
- Testing
- Empagliflozin, Liraglutide
- Where
- Denmark
- Volunteers
- 26,774 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes
This study is looking at the way insulin icodec stays and moves over time in the blood after injections in Chinese people with type 2 diabetes. Participants will get insulin icodec once a week for 6 weeks.
- Trial name
- NCT04857398
- Testing
- insulin icodec
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin
In this study the effect of ipragliflozin on glucose homeostasis in healthy subjects and T2DM subjects, and the effect of exposure of ipragliflozin on urinary glucose excretion and plasma glucose in T2DM subjects will be…
- Trial name
- NCT01611363
- Testing
- ASP1941
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Type 2 Diabetes Mellitus
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)
This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus.
- Trial name
- NCT02004886
- Testing
- MK-0893, Metformin
- Volunteers
- 74 people
- Sponsor
- Merck Sharp & Dohme LLC
Essential Hypertension
Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-folic Acid Tablets on reduction of blood pressure and plasma homocystein.
- Trial name
- NCT01848873
- Testing
- Amlodipine, amlodipine-FA tablet, low dose group, amlodipine-FA tablet ,high dose group
- Where
- 16 sites in China
- Volunteers
- 756 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Cardiovascular
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD1705 in participants with dyslipidemia.
- Trial name
- NCT06238466
- Testing
- AZD1705
- Where
- 5 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Phenylketonuria
Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)
This study is an international, multi-center, randomized, double-blind, placebo-controlled, two-treatment, two-period cross-over study to evaluate the pharmacodynamics, safety, tolerability and pharmacokinetics of a single oral…
- Trial name
- NCT04085666
- Testing
- CDX 6114
- Where
- 2 sites in Australia, Germany
- Volunteers
- 18 people
- Sponsor
- Société des Produits Nestlé (SPN)
Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in…
- Conditions
- Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
- Trial name
- NCT05355402
- Testing
- Olezarsen
- Where
- 24 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Type 2 Diabetes Mellitus
A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
The purpose of this study is to evaluate the glycemic control and safety of SHR-3167 and Insulin Degludec in type 2 diabetic participants treated with basal insulin with or without oral antidiabetic drugs.
- Trial name
- NCT07018453
- Testing
- SHR-3167, Insulin Degludec
- Where
- 2 sites in China
- Volunteers
- 173 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Biotinidase Deficiency
Study of ORL-1B in Patients With Biotinidase Deficiency
An Open-label, Single-arm, Phase 2 Study of Biotin in Patients With Biotinidase Deficiency.
- Trial name
- NCT03269045
- Testing
- ORL-1B
- Volunteers
- 20 people
- Sponsor
- Orpha Labs